EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a multi-center phase III randomized controlled study, designing to access whether the
efficacy of EGFR-TKI alone on patients with brain metastasis from non-small cell lung cancer
(NSCLC) harboring EGFR mutant type is not inferior to EGFR-TKI concurrent with whole brain
radiotherapy (WBRT), the primary end point is intracranial PFS (iPFS), while secondary
outcomes included overall survival (OS), objective response rate (ORR), evaluation of
cognitive function, quality of life (QoL) and adverse events.